The effect of topical atropine on the choroidal thickness of healthy children

Zhengwei Zhang, Yuanting Zhou, Zhifang Xie, Tiantian Chen, Yan Gu, Shui Lu, Zhifeng Wu, Zhengwei Zhang, Yuanting Zhou, Zhifang Xie, Tiantian Chen, Yan Gu, Shui Lu, Zhifeng Wu

Abstract

The purpose of the current study was to investigate the effect of topical atropine on choroidal thickness using spectral-domain optical coherence tomography. A total of 30 healthy eyes from 30 children were analyzed in this study. A single drop of 1% atropine gel was administered twice daily for a week. Choroidal thickness (CT) was measured using SD-OCT, and changes in CT before and after administration of the eye drops were analyzed at the subfovea and at 1.0-mm intervals (up to 3.0 mm) from the fovea at superior, inferior, nasal, and temporal locations. Pre- and post-cycloplegic axial length (AL) was also measured using the IOLMaster. We observed that administration of 1% atropine gel led to a significant increase in the choroidal thickness under the fovea and at all intervals from the fovea. The greatest change in CT was observed in the inferior meridian, while the nasal meridian exhibited the least change. AL did not significantly differ before and after cycloplegia, and there was no significant correlation between the changes in AL and subfoveal CT. It was concluded that administration of 1% atropine gel can significantly increase CT in the eyes of young Chinese children, albeit with different magnitude at different locations.

Figures

Figure 1. The changes of choroidal thickness…
Figure 1. The changes of choroidal thickness before and after 1-week administration of 1% atropine gel.
(A) T3, 3 mm temporal to the fovea; T2, 2 mm temporal to the fovea; T1, 1 mm temporal to the fovea; SF, subfovea; N3, 3 mm nasal to the fovea; N2, 2 mm nasal to the fovea; N1, 1 mm nasal to the fovea. (B) S3, 3 mm superior to the fovea; S2, 2 mm superior to the fovea; S1, 1 mm superior to the fovea; SF, subfovea; I3, 3 mm inferior to the fovea; I2, 2 mm inferior to the fovea; I1, 1 mm inferior to the fovea.
Figure 2. Bland-Altman plot analyses.
Figure 2. Bland-Altman plot analyses.
Bland-Altman plot of interobservers agreement on choroidal thickness measurements for all locations between the two observers before (A) and after 1-week administration of 1% atropine gel (B). Solid line indicates the average mean difference, whereas dotted lines delineate 95% limits of agreement (1.96 *SD). There was no specific trend to cause the difference between the two observers.

References

    1. Nickla D. L. & Wallman J. The multifunctional choroid. Prog Retin Eye Res. 29, 144–168 (2010).
    1. Neuhuber W. & Schrodl F. Autonomic control of the eye and the iris. Auton Neurosci. 165, 67–79 (2011).
    1. Arumugam B. & McBrien N. A. Muscarinic antagonist control of myopia: evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew. Invest Ophthalmol Vis Sci. 53, 5827–5837 (2012).
    1. Diether S. et al.. Effects of intravitreally and intraperitonally injected atropine on two types of experimental myopia in chicken. Exp Eye Res. 84, 266–274 (2007).
    1. Luft W. A., Ming Y. & Stell W. K. Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. Invest Ophthalmol Vis Sci. 44, 1330–1338 (2003).
    1. Kim M., Kwon H. J. & Lee S. C. Influence of mydriatics on choroidal thickness measurement using enhanced depth imaging-OCT. Optom Vis Sci. 89, 1150–1155 (2012).
    1. Hao J. et al.. Changes in subfoveal choroidal thickness before and after dilation in adolescents with mild and moderate myopia observed with enhanced depth imaging spectral-domain optical coherence tomography. Chin J Optom Ophthalmol Vis Sci. 15, 624–627 (2013).
    1. Mwanza J. C., Sayyad F. E., Banitt M. R. & Budenz D. L. Effect of pupil dilation on macular choroidal thickness measured with spectral domain optical coherence tomography in normal and glaucomatous eyes. Int Ophthalmol. 33, 335–341 (2013).
    1. Sander B. P., Collins M. J. & Read S. A. The effect of topical adrenergic and anticholinergic agents on the choroidal thickness of young healthy adults. Exp Eye Res. 128, 181–189 (2014).
    1. Kara N. et al.. Effects of two commonly used mydriatics on choroidal thickness: direct and crossover effects. J Ocul Pharmacol Th. 30, 366–370 (2014).
    1. Yuvacı İ. et al.. An evaluation of effects of different mydriatics on choroidal thickness by examining anterior chamber parameters: the ccheimpflug imaging and enhanced depth imaging-OCT study. J Ophthalmol. 2015, 981274, 10.1155/2015/981274 (2015).
    1. Chia A. et al.. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology. 119, 347–354 (2012).
    1. Chia A., Lu Q. S. & Tan D. Five-year clinical trial on atropine for the treatment of ayopia 2. Ophthalmology. 123, 391–399 (2015).
    1. Shih K. C. et al.. Use of atropine for prevention of childhood myopia progression in clinical practice. Eye Contact Lens. 42 (2016).
    1. Morgan I. G. & He M. An important step forward in myopia prevention: low-dose atropine. Ophthalmology. 123, 232–233 (2016).
    1. Read S. A., Alonso-Caneiro D., Vincent S. J. & Collins M. J. Longitudinal changes in choroidal thickness and eye growth in childhood. Invest Ophthalmol Vis Sci. 56, 3103–3112 (2015).
    1. Yen M. Y., Liu J. H., Kao S. C. & Shiao C. H. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 21, 180–182 (1989).
    1. Nickla D. L. & Kristen Totonelly M. S. Choroidal thickness predicts ocular growth in normal chicks but not in eyes with experimentally altered growth. Clin Exp Optom. 98, 564–570 (2015).
    1. Woodman E. C., Read S. A. & Collins M. J. Axial length and choroidal thickness changes accompanying prolonged accommodation in myopes and emmetropes. Vision Res. 72, 34–41 (2012).
    1. Woodman-Pieterse E. C., Read S. A., Collins M. J. & Alonso-Caneiro D. Regional changes in choroidal thickness associated with cccommodation. Invest Ophthalmol Vis Sci. 56, 6414–6422 (2015).
    1. Chiang S. T., Phillips J. R. & Backhouse S. Effect of retinal image defocus on the thickness of the human choroid. Ophthalmic Physiol Opt. 35, 405–413 (2015).
    1. Li M. et al.. Change in choroidal thickness and the relationship with accommodation following myopic excimer laser surgery. Eye (Lond). 30, 972–978 (2016).
    1. Meriney S. D. & Pilar G. Cholinergic innervation of the smooth muscle cells in the choroid coat of the chick eye and its development. J Neurosci. 7, 3827–3839 (1987).
    1. Nickla D. L. & Schroedl F. Parasympathetic influences on emmetropization in chicks: evidence for different mechanisms in form deprivation vs negative lens-induced myopia. Exp Eye Res. 102, 93–103 (2012).
    1. Nickla D. L., Zhu X. & Wallman J. Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning. Ophthalmic Physiol Opt. 33, 245–256 (2013).
    1. Junghans B., Crewther S. & Crewther D. Choroidal lympthatics: An active storage reservoir. Invest Ophthalmol Vis Sci. 39, S504 (1998).
    1. Kerlavage A. R., Fraser C. M., Chung F. Z. & Venter J. C. Molecular structure and evolution of adrenergic and cholinergic receptors. Proteins. 1, 287–301 (1986).
    1. Näreoja K. et al.. Adrenoceptor activity of muscarinic toxins identified from mamba venoms. Br J Pharmacol. 164, 538–550 (2011).
    1. Chang K. C. & Hahn K. H. Is alpha-adrenoceptor blockade responsible for atropine flush? Eur J Pharmacol. 284, 331–334 (1995).
    1. Kwan C. Y., Zhang W. B., Kwan T. K. & Sakai Y. In vitro relaxation of vascular smooth muscle by atropine: involvement of K+ channels and endothelium. Naunyn Schmiedebergs Arch Pharmacol. 368, 1–9 (2003).
    1. Ayajiki K., Tanaka T., Okamura T. & Toda N. Evidence for nitroxidergic innervation in monkey ophthalmic arteries in vivo and in vitro. Am J Physiol Heart Circ Physiol. 279, H2006–2012 (2000).
    1. Carr B., Nathanson N. & Stell W. Atropine prevents myopia via a nitric oxide-mediated relay. Invest Ophthalmol Vis Sci. 54, 3677–3677 (2013).
    1. Nickla D. L. et al.. Inhibiting the transient choroidal thickening response using the nitric oxide synthase inhibitor l-NAME prevents the ameliorative effects of visual experience on ocular growth in two different visual paradigms. Exp Eye Res. 83, 456–464 (2006).
    1. Schwahn H. N., Kaymak H. & Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Vis Neurosci. 17, 165–176 (2000).
    1. Dhillon B., Armani J. & Nickla D. The ocular growth inhibition effected by dopamine agonists and atropine is associated with transient increases in choroidal thickness in chicks. Invest Ophthalmol Vis Sci. 49, 1732–1732 (2008).
    1. Smith S. A. Factors determining the potency of mydriatic drugs in man. Br J Clin Pharmacol. 3, 503–507 (1976).
    1. Mizuno K. et al.. Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina. Invest Ophthalmol Vis Sci. 50, 2839–2847 (2009).
    1. Branchini L. A. et al.. Analysis of choroidal morphologic features and vasculature in healthy eyes using spectral-domain optical coherence tomography. Ophthalmology. 120, 1901–1908 (2013).
    1. Adhi M., Brewer E., Waheed N. K. & Duker J. S. Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography. JAMA Ophthalmol. 131, 1267–1274 (2013).
    1. Adhi M. et al.. Analysis of the thickness and vascular layers of the choroid in eyes with geographic atrophy using spectral-domain optical coherence tomography. Retina. 34, 306–312 (2014).
    1. Park K. A. & Oh S. Y. An optical coherence tomography-based analysis of choroidal morphologic features and choroidal vascular diameter in children and adults. Am J Ophthalmol. 158, 716–723 (2014).
    1. Sonoda S. et al.. Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images. Am J Ophthalmol. 159, 1123–1131 (2015).
    1. Lam A. K., Chan R. & Pang P. C. The repeatability and accuracy of axial length and anterior chamber depth measurements from the IOLMaster. Ophthalmic Physiol Opt. 21, 477–483 (2001).
    1. Carkeet A. et al.. Repeatability of IOLMaster biometry in children. Optom Vis Sci. 81, 829–834 (2004).
    1. Brown J. S. et al.. In vivo human choroidal thickness measurements: evidence for diurnal fluctuations. Invest Ophthalmol Vis Sci. 50, 5–12 (2009).
    1. Tan C. S., Ouyang Y., Ruiz H. & Sadda S. R. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 53, 261–266 (2012).
    1. Zhang Z. et al.. Changes in choroidal thickness after panretinal photocoagulation for diabetic retinopathy: a 12-week longitudinal study. Invest Ophthalmol Vis Sci. 56, 2631–2638 (2015).
    1. McAlinden C., Khadka J. & Pesudovs K. Statistical methods for conducting agreement (comparison of clinical tests) and precision (repeatability or reproducibility) studies in optometry and ophthalmology. Ophthalmic Physiol Opt. 31, 330–338 (2011).
    1. Bland Martin J. & Altman Douglas G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1, 931–936 (1986).

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren